ADMP - Adamis Pharmaceuticals Corporation
| Previous Close | 1.0600 |
| Open | 1.0500 |
| Bid | 1.0500 x 21500 |
| Ask | 1.1500 x 3000 |
| Day's Range | 1.0400 - 1.0500 |
| 52 Week Range | 0.9300 - 4.2500 |
| Volume | 33,935 |
| Avg. Volume | 476,082 |
| Market Cap | 64.51M |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8310 |
| Earnings Date | Nov 7, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.37 |
- Thomson Reuters StreetEvents
Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 Adamis Pharmaceuticals Corp Earnings Call
- GlobeNewswire
Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
Ulcers are common in the majority of horses that are subject to stress and can affect horses at any age. Examples of horses under stress include racehorses, endurance horses, dressage horses, hunters, jumpers, 3-day eventers and any type of rodeo horse. In general, horses that are in active training tend to have a prevalence of ulcers in the range of 90 to 95%. Historically, ulcers have been known to negatively affect feeding habits and performance on the track.
- Zacks
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
Adamis (ADMP) delivered earnings and revenue surprises of -33.33% and -1.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update
SAN DIEGO, Aug. 08, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a.
- Simply Wall St.
Did Changing Sentiment Drive Adamis Pharmaceuticals's (NASDAQ:ADMP) Share Price Down A Painful 73%?
Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply accept every...
- GlobeNewswire
Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO, Aug. 05, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and.
- Zacks
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today the pricing of its previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase up to 12,000,000 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined public offering price of $1.00, resulting in gross proceeds of approximately $12,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company and excluding the proceeds from the exercise of any warrants.
- GlobeNewswire
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose, announced today that it intends to offer to sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants to purchase shares of its common stock offered in the public offering.
- Zacks
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.
- Zacks
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
Masimo's (MASI) recent developments likely to show on second-quarter results.
- Zacks
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that Adamis and Belcher Pharmaceuticals, LLC (“Belcher”) agreed to settle all previously filed litigation between the parties, including the case filed by Adamis in the United States District Court for the Middle District of Florida in which Adamis was seeking a declaratory judgment of non-infringement of certain patents in which Belcher claimed rights, relating to certain methods of preparing epinephrine solutions (“Patent Case”), and the inter partes review proceeding filed by Adamis in the United States Patent and Trademark Office requesting a formal review the validity of certain aspect of Belcher’s patents (“IPR”).
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company’s SYMJEPI™ (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products are FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis is developing additional products, including the company’s ZIMHI™ naloxone injection product candidate for the treatment of opioid overdose, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs and certain nonsterile drugs for human and veterinary use, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
SAN DIEGO, July 09, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail.
- Reuters
Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen. The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner. Mylan dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.
- Simply Wall St.
Have Insiders Been Selling Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- GlobeNewswire
Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
SAN DIEGO, June 11, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the receipt of.
- GlobeNewswire
Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
SAN DIEGO, May 21, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that on May 20, 2019, it received notice that it had been named and served as a.
- GlobeNewswire
Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proposed brand name for the company’s high dose naloxone product candidate. The notification to the company from the FDA noted that after review, the proposed proprietary name “Zimhi™” was conditionally acceptable. Naloxone is an opioid antagonist used to treat narcotic overdoses. Naloxone, which is generally considered the drug of choice for immediate administration for opioid overdose, blocks or reverses the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl.
- Thomson Reuters StreetEvents
Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 Adamis Pharmaceuticals Corp Earnings Call
- Zacks
Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates
Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Adamis: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The biopharmaceutical company posted revenue of $4.9 million in the period. In the final minutes of trading on Thursday, ...
- GlobeNewswire
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
On January 16, 2019, we announced that Sandoz had launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the U.S. market. SYMJEPI will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz has significant experience and knowledge, followed by anticipated introduction into the retail market. We also anticipate that Sandoz will launch the lower dose SYMJEPI (epinephrine) 0.15 mg Injection product in the U.S. markets. With the continued rollout of SYMJEPI into the retail market, the company anticipates that the revenue stream to Adamis will increase in future quarters.
